	US 12,329,802 B2
	Focal treatment of prostate cancer
Paul Averback, Nassau (BS)
Assigned to NYMOX CORPORATION, Nassau (BS)
Filed by Nymox Corporation, New Providence (BS)
Filed on May 10, 2022, as Appl. No. 17/740,755.
Application 17/740,755 is a continuation of application No. 16/528,326, filed on Jul. 31, 2019, granted, now 11,331,374.
Prior Publication US 2022/0323543 A1, Oct. 13, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/17 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)

CPC A61K 38/1761 (2013.01) [A61P 35/00 (2018.01); A61K 45/06 (2013.01)]

11 Claims

1. A method of reducing cancer incidence, reducing cancer grade, and reducing cancer progression in a mammal having a low grade unifocal prostate cancer tumor comprising:

identifying a mammal having a low grade unifocal prostate cancer tumor; and

administering to the low grade unifocal prostate cancer tumor of the mammal so identified, the administering by intraprostatic injection directly to the low grade unifocal prostate cancer tumor a composition comprising a therapeutically effective amount of fexapotide triflutate (FT);

wherein administering FT to the low grade unifocal prostate cancer tumor reduces cancer incidence, reduces cancer grade, and reduces prostate cancer progression in the entire hemi-prostate where the initial low grade unifocal prostate cancer tumor was located and treated.